DUBLIN--(BUSINESS WIRE)--The "Molecular Diagnostics for Cancer - Markets, Strategies and Trends. Forecasts by Cancer Type, Including Companion Dx and by Country with Executive and Consultant Guides and COVID-19 Pandemic Recession Forecast Revisions. 2021 to 2025" report has been added to ResearchAndMarkets.com's offering.
A market with fundamental growth factors is impacted by the COVID-19 Pandemic. Molecular Diagnostics for Cancer is positioned to directly benefit from the explosion in genomics knowledge but shifting resources to deal with the COVID-19 emergency may interrupt growth. Learn all about it in this new report.
The publisher includes a special segment, Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry. And now over 130 companies are profiled. A range of dynamic trends are pushing market growth and company valuations.
Working against this dynamic market are the forces of the COVID-19 Driven Recession. The publisher's latest numbers factor in the different COVID-19 forces, their timing, and their effect on growth.
Exciting technical developments especially in the area of pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage.
This report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2020 United States Medicare Fee Payment Schedules to help understand test pricing in detail. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions.
Companies Mentioned
- Abbott Diagnostics
- AccuraGen Inc
- Adaptive Biotechnologies
- Aethlon Medical
- Agena Bioscience, Inc
- Agilent
- Anchor Dx
- ANGLE plc
- ApoCell, Inc.
- ArcherDx, Inc.
- ARUP Laboratories
- Asuragen
- AVIVA Biosciences
- Baylor Miraca Genetics Laboratories
- Beckman Coulter, Inc.
- BGI Genomics Co. Ltd
- Bio-Rad Laboratories, Inc
- Bio-Reference Laboratories
- Bio-Techne
- Bioarray Genetics
- Biocartis
- Biocept, Inc
- Biodesix Inc.
- BioFluidica
- BioGenex
- Biolidics Ltd
- bioMerieux Diagnostics
- Bioneer Corporation
- Bioview
- Bolidics
- Boreal Genomics
- Bristol-Myers Squibb
- Cancer Genetics
- Caris Molecular Diagnostics
- CellMax Life
- Cepheid (now Danaher)
- Charles River Laboratories
- Chronix Biomedical
- Circulogene
- Clinical Genomics
- Cynvenio
- Cytolumina Technologies Corp.
- CytoTrack
- Datar Cancer Genetics Limited
- Diagnologix LLC
- Diasorin S.p.A.
- Enzo Life Sciences, Inc.
- Epic Sciences
- And Many More Companies!
Key Topics Covered:
1. Introduction and Market Definition
2. Market Overview
3. Market Trends
3.1 Factors Driving Growth
3.1.1 New Diagnostics Create New Markets
3.1.2 New Roles for Diagnostics
3.1.3 Longevity and Outcomes
3.1.3 Expanding the Pharmaceutical Toolbox
3.1.4 Regulatory Retreat
3.2 Factors Limiting Growth
3.2.1 Falling Prices
3.2.2 Lower Costs
3.2.3 COVID Pandemic
3.2.4 Wellness has a Downside
3.3 Instrumentation and Automation
3.3.1 Instruments Key to Market Share
3.3.2 Bioinformatics Plays a Role
3.4 Diagnostic Technology Development
3.4.1 Next Generation Sequencing
3.4.2 Shifting Role of Diagnostics
3.4.3 Multiplexing and Foundation One
3.4.4 Pharmacogenomics Technology
3.4.5 Whole Genome Sequencing
3.4.6 Gene Editing and Gene Therapy
4. Molecular Diagnostics Recent Developments
- Recent Developments - Importance and How to Use This Section
- Importance of These Developments
- How to Use This Section
- Biocartis Collaborating With GeneproDx, Endpoint Health on Tests for Idylla Platform
- Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test
- Metastatic Cancer Markers Identified in Clinical WGS Study
- Stitch Bio Bets on CRISPR Tech
- Bayer, LifeLabs Launch Free NTRK Genetic Testing Program
- Foundation Medicine Liquid Biopsy Gets FDA Approval for Multiple Companion Dx
- Progress, Challenges in Liquid Biopsy Reimbursement
- Israeli Startup Curesponse Raises $6M
- Coronavirus Pandemic Bites into European Cancer Research
- Veracyte's Prosigna IDs Patients Likely to Benefit from Aggressive Chemotherapy
- Combining CRISPR and Nanopore Sequencing
- Liquid Biopsy Detects Cancer Early via Cell Clusters
- Roche, Illumina unveil 15-year cancer diagnostic tie-up
- Saga, Servier Sign Liquid Biopsy Services Deal
- Home urine test could revolutionize diagnosis of prostate cancer
- Cancer Gene Tests Cost-Effective for Breast Cancer Patients
- Personal Genome Diagnostics Gets CE Mark for Elio Tissue Assay
- OncoCyte to Buy Cancer Testing Company Razor Genomics
- Blood Test May Eliminate Need for Exploratory Surgery
- NGS Cancer Panel Receives New York State Conditional Approval
- Biocartis Inks Cancer CDx Deal With Bristol-Myers Squibb
5. Profiles of Key MDx Companies
6. The Global Market for MDx Cancer
6.1 MDx Cancer - Global Market Overview by Country
6.1.1 Table - Global Market by Country
6.1.2 Chart - Global Market by Country
7. Global MDx Cancer Markets - By Type of Cancer
8. Cancer Treatment and Trials
8.1 FDA Cancer Drug Approvals by Year
8.2 Clinical Trials Started 2010 to 2016
8.3 Prevalence of Cancer Treatments - 2015
For more information about this report visit https://www.researchandmarkets.com/r/o9ny2e
